Citation 67056

LEE-HUANG,S: KUNG,HF: HUANG,PAL: HUANG,PHL: LI,BQ: HUANG,P: HUANG,HI: CHEN,HC:. (1991). A NEW CLASS OF ANTI-HIV AGENTS: GAP31, DAPS 30 AND 32.. 291(1)

Citation Details

Title	A NEW CLASS OF ANTI-HIV AGENTS: GAP31, DAPS 30 AND 32.
Authors	LEE-HUANG,S: KUNG,HF: HUANG,PAL: HUANG,PHL: LI,BQ: HUANG,P: HUANG,HI: CHEN,HC:
Year	1991
Volume	291
Issue	1

Summary

Year: 1991

Journal: Unknown

Organisms and Their Experiments (2)

Suregada multiflora (EUPHORBIACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	ISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	GLENONIUM ANTI-HIV PROTEIN GAP-31	None
2	SYNCYTIA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
3	REVERSE TRANSCRIPTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
5	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	INACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	INACTIVE
7	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
8	ANTIVIRAL ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
9	ANTIVIRAL ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE
10	TOXICITY ASSESSMENT(QUANTITATIVE)	TOXICITY MARKER CODEPHARMACOLOGY OF COMPOUND - IN VIVO	GLENONIUM ANTI-HIV PROTEIN GAP-31	.
11	RIBOSOME INACTIVATION	PHARMACOLOGY OF COMPOUND - IN VITRO	GLENONIUM ANTI-HIV PROTEIN GAP-31	ACTIVE

Dianthus caryophyllus (CARYOPHYLLACEAE)

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	Not specified	ISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	DIANTHUS ANTI-HIV PROTEIN DAP-30	None
2	SYNCYTIA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
3	REVERSE TRANSCRIPTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
4	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
5	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
6	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
7	CYTOTOXIC ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
8	TOXICITY ASSESSMENT(QUANTITATIVE)	TOXICITY MARKER CODEPHARMACOLOGY OF COMPOUND - IN VIVO	DIANTHUS ANTI-HIV PROTEIN DAP-30	.
9	RIBOSOME INACTIVATION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-30	ACTIVE
10	Not specified	ISOLATION OF A COMPOUND WITH NOVEL STRUCTURE	DIANTHUS ANTI-HIV PROTEIN DAP-32	None
11	SYNCYTIA INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE
12	REVERSE TRANSCRIPTASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE
13	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE
14	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	INACTIVE
15	PROTEIN SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	INACTIVE
16	DNA SYNTHESIS INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITROANTICANCER AND/OR CYTOTOXICITY MARKER CODE	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE
17	ANTIVIRAL ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITROANTIBIOTIC MARKER CODE. (USE WITH 14XXX MPASPA)	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE
18	TOXICITY ASSESSMENT(QUANTITATIVE)	TOXICITY MARKER CODEPHARMACOLOGY OF COMPOUND - IN VIVO	DIANTHUS ANTI-HIV PROTEIN DAP-32	.
19	RIBOSOME INACTIVATION	PHARMACOLOGY OF COMPOUND - IN VITRO	DIANTHUS ANTI-HIV PROTEIN DAP-32	ACTIVE

Show SPARQL Queries (1)